Perinaphthenone compound and use thereof

A compound, or a pharmaceutically acceptable salt, an ester, a stereoisomer, a prodrug, and a solvate thereof, wherein the compound has the following structure:

• wherein,
• the valence bond at 1 and 2 represents a single or double bond, and 1 and 2 are not both double bonds;
• R1 to R18 are independently selected from:
• H, alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, halogen, —CN, —NO2, —CORA, —C(O)ORA, —OCORA, —C(O)NRARB, —CH═NRA, —ORA, —OC(O)RA, S(O)t—RA, —S(O)t—NRARB, —NRARB, and —NRAC(O)RB;
• optionally, the H on each group may be substituted with one or more groups selected from:
• halogen, —CN, —CF3, —NO2, —CHO, —COOH, —C(O)NH2, —OH, —OC(O)H, —SH, —S(O)2H, and —NH2;
• R19 and R20 are independently selected from:
• H, alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, and heterocyclylalkyl;
• optionally, the H on each group may be substituted with one or more groups selected from:
• substituted or unsubstituted heterocyclyl, halogen, —CN, —NO2, —CORA, —C(O)ORA, —C(O)NRARB, —CH═NRA, —ORA, —OC(O)RA, —S(O)t—RA, —S(O)t—NRARB, —NRARB, and —NRAC(O)RB;
• or, R19 and R20, together with the carbon atom to which they are attached, form substituted or unsubstituted cycloalkyl or heterocyclyl;
• or, R17 and R19, together with the carbon atoms to which they are attached, form substituted or unsubstituted cycloalkyl or heterocyclyl;
• t is selected from 0, 1, and 2;
• each RA and RB are independently selected from:
• H, alkyl, cycloalkyl, alkenyl, aryl, heterocyclyl, and halogen.